Group at a glance Broad product portfolio Hikma sells 353 pharmaceutical products in 728 dosage strengths and forms in 47 countries.
40 of these products are sold under promotion and distribution agreements with or licences from 16 originator pharmaceutical companies and three generic pharmaceutical companies.
The majority of Hikmas operations are in the Middle East and North Africa MENA, the United States and Europe.
Branded Generics Injectables 2007 Revenue 2007 Revenue 2007 Revenue $198.9m $124.2m $121.2m Products Products Products 236 44 73 branded generic products including non-branded solid generic products branded and non-branded injectable products 2 33 in-licensed products including seven in-licensed products Key markets Key markets Key markets MENA US MENA, US, Europe Top products Top products Top products 3 Amoclan ABC blue Cefazolin Omnicef Lithium carb SR Ceftizoxime Penamox Doxycycline Ceftriaxone Prograf Methocarbamol Cefuroxime Suprax Lisinopril Vancomycin 1.
A further five in-licensed products are pending launch.
Branded in-licenced products include five in-licensed products marketed only in Egypt.
And other co-amoxiclav Hikma brands, including Megamox.
Diversified business Broad geographic coverage 07 06 07 06 Revenue by business segment Revenue by region 1 Branded 44.3% 41.0% 1 Middle East and North Africa 51.1% 49.7% 2 Generics 27.7% 35.9% 2 United States 32.0% 40.9% 3 Injectables 27.0% 21.3% 3 Europe and ROW 17.0% 9.3% 4 Other 1.0% 1.8% 4 3 3 3 4 3 1 1 1 2 1 2 2 2 Our markets R&D centres Manufacturing plants 14 Hikma Pharmaceuticals PLC Annual report 2007
